ECSP099476A - Compuestos carboxamida y su uso como inhibidores de calpaína - Google Patents
Compuestos carboxamida y su uso como inhibidores de calpaínaInfo
- Publication number
- ECSP099476A ECSP099476A EC2009009476A ECSP099476A ECSP099476A EC SP099476 A ECSP099476 A EC SP099476A EC 2009009476 A EC2009009476 A EC 2009009476A EC SP099476 A ECSP099476 A EC SP099476A EC SP099476 A ECSP099476 A EC SP099476A
- Authority
- EC
- Ecuador
- Prior art keywords
- carboxamide compounds
- compounds
- calpain inhibitors
- carboxamide
- calpain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se relaciona con compuestos carboxamida novedosos y su uso para la fabricación de un medicamento. Los compuestos carboxamida son inhibidores de calpaína (cisteína proteasas dependientes del calcio). Por lo tanto, la invención también se refiere al uso de dichos compuestos carboxamida para tratar un trastorno asociado con una alta actividad de calpaína.Los compuestos carboxamida son compuestos de la fórmula general I donde R1, R2, R3a, R3b, W, Y y X tienen los significados que se mencionan en las reivindicaciones y la descripción, los tautómeros de los mismos y las sales de los mismos apropiados para uso farmacéutico. En particular, los compuestos tienen la fórmula general I-A.a' y I-A.a'' en donde m, E, R1, R3a, R3b, R2, Ry, Rw y Rw6 tienen los valores que se mencionan en la memoria descriptiva, n es 0, 1 o 2, sus tautómeros y sales aceptables para uso farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06127369 | 2006-12-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP099476A true ECSP099476A (es) | 2009-07-31 |
Family
ID=39226751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2009009476A ECSP099476A (es) | 2006-12-29 | 2009-06-29 | Compuestos carboxamida y su uso como inhibidores de calpaína |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US8436034B2 (es) |
| EP (2) | EP2439205B1 (es) |
| JP (1) | JP5295976B2 (es) |
| KR (3) | KR101578674B1 (es) |
| CN (1) | CN101616908B (es) |
| AR (2) | AR064693A1 (es) |
| AT (1) | ATE544758T1 (es) |
| AU (1) | AU2007341232B2 (es) |
| BR (1) | BRPI0721298A2 (es) |
| CA (1) | CA2673580C (es) |
| CL (1) | CL2007003879A1 (es) |
| CO (1) | CO6190617A2 (es) |
| DK (1) | DK2439205T3 (es) |
| EC (1) | ECSP099476A (es) |
| ES (2) | ES2381879T3 (es) |
| GT (1) | GT200900186A (es) |
| HK (1) | HK1138833A1 (es) |
| IL (2) | IL199447A (es) |
| MX (1) | MX2009007050A (es) |
| MY (1) | MY147780A (es) |
| NZ (2) | NZ599860A (es) |
| PE (1) | PE20081609A1 (es) |
| PL (1) | PL2439205T3 (es) |
| PT (1) | PT2439205E (es) |
| RU (2) | RU2485114C2 (es) |
| TW (1) | TWI405571B (es) |
| UA (1) | UA100501C2 (es) |
| UY (1) | UY30850A1 (es) |
| WO (1) | WO2008080969A1 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0721298A2 (pt) * | 2006-12-29 | 2014-03-25 | Abbott Gmbh & Co Kg | Composto de carboxamida e seus usos como inibidores de calpaína |
| TWI453019B (zh) * | 2007-12-28 | 2014-09-21 | Abbvie Deutschland | 甲醯胺化合物 |
| BRPI0918430A2 (pt) * | 2008-08-14 | 2015-11-24 | Bayer Cropscience Ag | 4-fenil-1h-pirazóis inseticidas. |
| TWI519530B (zh) * | 2009-02-20 | 2016-02-01 | 艾伯維德國有限及兩合公司 | 羰醯胺化合物及其作為鈣蛋白酶（ｃａｌｐａｉｎ）抑制劑之用途 |
| US8236798B2 (en) * | 2009-05-07 | 2012-08-07 | Abbott Gmbh & Co. Kg | Carboxamide compounds and their use as calpain inhibitors |
| ES2570569T3 (es) * | 2009-09-28 | 2016-05-19 | Hoffmann La Roche | Compuestos de benzoxazepina como inhibidores de la PI3K y métodos de uso |
| US8598211B2 (en) | 2009-12-22 | 2013-12-03 | Abbvie Inc. | Carboxamide compounds and their use as calpain inhibitors IV |
| US9051304B2 (en) | 2009-12-22 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Carboxamide compounds and their use as calpain inhibitors V |
| CN102939126B (zh) | 2010-04-30 | 2015-09-16 | 雅培心脏血管***股份有限公司 | 呈现迅速膨胀和收缩的改进型球囊导管 |
| CA2819087A1 (en) * | 2010-12-09 | 2012-06-14 | AbbVie Deutschland GmbH & Co. KG | Carboxamide compounds and their use as calpain inhibitors v |
| US8669370B2 (en) | 2011-01-26 | 2014-03-11 | Sanofi | Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals |
| WO2013126283A1 (en) | 2012-02-20 | 2013-08-29 | E. I. Du Pont De Nemours And Company | Fungicidal pyrazoles |
| JP2015512427A (ja) * | 2012-04-03 | 2015-04-27 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | カルボキサミド化合物およびそれのカルパイン阻害薬ｖとしての使用 |
| BR112015020350B1 (pt) | 2013-03-29 | 2023-04-25 | Takeda Pharmaceutical Company Limited | Derivados de 6-(5-hidróxi-1h-pirazol-1-il)nicotinamida, sua composição farmacêutica e seus usos |
| CA2920815C (en) * | 2013-08-14 | 2021-09-21 | Kalvista Pharmaceuticals Limited | Inhibitors of plasma kallikrein |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| MX2018007527A (es) | 2015-12-22 | 2018-09-07 | Syngenta Participations Ag | Derivados de pirazol activos como pesticidas. |
| CN107827833A (zh) * | 2016-01-26 | 2018-03-23 | 绍兴瑞康生物科技有限公司 | 三嗪类多功能光吸收抗氧剂类化合物及其制备方法和应用 |
| EP3426674A4 (en) | 2016-03-09 | 2019-08-14 | Blade Therapeutics, Inc. | CYCLIC KETO AMID COMPOUNDS AS CALPAIN MODULATORS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| SI3464271T1 (sl) | 2016-05-31 | 2020-10-30 | Kalvista Pharmaceuticals Limited | Derivati pirazola kot inhibitorji plazemskega kalikreina |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| AU2017292646A1 (en) | 2016-07-05 | 2019-02-07 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
| SG10201912574WA (en) * | 2016-09-28 | 2020-02-27 | Blade Therapeutics Inc | Calpain modulators and therapeutic uses thereof |
| RU2767652C2 (ru) | 2017-08-16 | 2022-03-18 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Новые соединения |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| DK3716952T3 (da) | 2017-11-29 | 2022-03-14 | Kalvista Pharmaceuticals Ltd | Doseringsformer omfattende en plasmakallikrein-inhibitor |
| RU2020130022A (ru) * | 2018-03-28 | 2022-05-04 | Блэйд Терапьютикс, Инк. | Модуляторы кальпаина и их терапевтическое применение |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH21213A (en) | 1984-10-26 | 1987-08-21 | Fujisawa Pharmaceutical Co | Benzene- and pyrazole- fused heterocyclic compound and pharmaceutical composition comprising the same |
| US4826835A (en) | 1985-10-23 | 1989-05-02 | Rorer Pharmaceutical Corporation | Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in the treatment of congestive heart failure |
| US4743608A (en) | 1986-07-15 | 1988-05-10 | Rorer Pharmaceutical Corporation | Pyridone-pyridyl-imidazolyl and triazolyl compounds and their use as cardiotonic agents |
| US4888352A (en) | 1989-03-22 | 1989-12-19 | Sterling Drug Inc. | 3,4, or 5-aryl-1H-pyrazole-1-alkanamides as antiarrhythmic agents, compositions and use |
| GB9412603D0 (en) * | 1994-06-23 | 1994-08-10 | Sandoz Ltd | Organic compounds |
| DE19642591A1 (de) | 1996-10-15 | 1998-04-16 | Basf Ag | Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung |
| DE19650975A1 (de) | 1996-12-09 | 1998-06-10 | Basf Ag | Neue heterocyclisch substituierte Benzamide und deren Anwendung |
| WO1998025883A1 (de) | 1996-12-11 | 1998-06-18 | Basf Aktiengesellschaft | Ketobenzamide als calpain-inhibitoren |
| US6127556A (en) | 1996-12-31 | 2000-10-03 | G. D. Searle & Co. | Epoxide formation by continuous in-situ synthesis process |
| US6083944A (en) * | 1997-10-07 | 2000-07-04 | Cephalon, Inc. | Quinoline-containing α-ketoamide cysteine and serine protease inhibitors |
| DE19818614A1 (de) | 1998-04-20 | 1999-10-21 | Basf Ag | Neue substituierte Amide, deren Herstellung und Anwendung |
| DE19817459A1 (de) * | 1998-04-20 | 1999-10-21 | Basf Ag | Neue heterozyklische substituierte Amide, Herstellung und Anwendung |
| DE19817461A1 (de) | 1998-04-20 | 1999-10-21 | Basf Ag | Neue substituierte Benzamide, deren Herstellung und Anwendung |
| SK14512000A3 (sk) | 1998-04-20 | 2001-04-09 | Basf Aktiengesellschaft | Substituované amidy, ich príprava a použitie |
| EP1080083A1 (de) | 1998-04-20 | 2001-03-07 | Basf Aktiengesellschaft | Neue heterocyclisch substituierte amide mit cystein-protease hemmender wirkung |
| IL138402A0 (en) | 1998-04-20 | 2001-10-31 | Basf Ag | Heterocyclically substituted amides used as calpain inhibitors |
| KR20010043799A (ko) * | 1998-05-25 | 2001-05-25 | 스타르크, 카르크 | 헤테로고리 치환된 신규 아미드, 그의 제조 및 그의 용도 |
| AR018915A1 (es) * | 1998-06-24 | 2001-12-12 | Smithkline Beecham Corp | Inhibidores de proteasas diacilhidrazinicos, composicion farmaceutica que la comprenden, usos de los mismos para la manufactura de un medicamento, unprocedimiento de fabricacion de dichos compuestos |
| WO2001068645A2 (en) * | 2000-03-15 | 2001-09-20 | Axys Pharmaceuticals, Inc. | N-cyanomethylcarboxamides and their use as protease inhibitors |
| JP2001261675A (ja) | 2000-03-21 | 2001-09-26 | Mitsui Chemicals Inc | ピラゾリン誘導体またはテトラヒドロピリダジン誘導体を含有する医薬 |
| US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| DE10114762A1 (de) | 2001-03-26 | 2002-10-02 | Knoll Gmbh | Verwendung von Cysteinprotease-Inhibitoren |
| SI1482924T1 (sl) * | 2002-03-05 | 2008-12-31 | Merck Frosst Canada Ltd | Katepsin cistein proteazni inhibitorji |
| EP1610263A1 (en) | 2004-06-18 | 2005-12-28 | Sicpa Holding S.A. | Item carrying at least two data storage elements |
| WO2006080439A1 (ja) | 2005-01-28 | 2006-08-03 | Taisho Pharmaceutical Co., Ltd. | 三環性化合物 |
| BRPI0721298A2 (pt) * | 2006-12-29 | 2014-03-25 | Abbott Gmbh & Co Kg | Composto de carboxamida e seus usos como inibidores de calpaína |
| TWI453019B (zh) * | 2007-12-28 | 2014-09-21 | Abbvie Deutschland | 甲醯胺化合物 |
-
2007
- 2007-12-28 BR BRPI0721298-4A patent/BRPI0721298A2/pt not_active IP Right Cessation
- 2007-12-28 CL CL200703879A patent/CL2007003879A1/es unknown
- 2007-12-28 CN CN200780051850.2A patent/CN101616908B/zh not_active Expired - Fee Related
- 2007-12-28 TW TW096150930A patent/TWI405571B/zh not_active IP Right Cessation
- 2007-12-28 MY MYPI20092635A patent/MY147780A/en unknown
- 2007-12-28 ES ES07866322T patent/ES2381879T3/es active Active
- 2007-12-28 KR KR1020097016007A patent/KR101578674B1/ko not_active IP Right Cessation
- 2007-12-28 RU RU2009129119/04A patent/RU2485114C2/ru not_active IP Right Cessation
- 2007-12-28 UA UAA200907938A patent/UA100501C2/uk unknown
- 2007-12-28 AR ARP070105965A patent/AR064693A1/es unknown
- 2007-12-28 AT AT07866322T patent/ATE544758T1/de active
- 2007-12-28 PT PT111950994T patent/PT2439205E/pt unknown
- 2007-12-28 AU AU2007341232A patent/AU2007341232B2/en not_active Ceased
- 2007-12-28 UY UY30850A patent/UY30850A1/es not_active Application Discontinuation
- 2007-12-28 JP JP2009543479A patent/JP5295976B2/ja not_active Expired - Fee Related
- 2007-12-28 EP EP11195099.4A patent/EP2439205B1/en not_active Not-in-force
- 2007-12-28 WO PCT/EP2007/064617 patent/WO2008080969A1/en active Application Filing
- 2007-12-28 DK DK11195099.4T patent/DK2439205T3/da active
- 2007-12-28 PL PL11195099T patent/PL2439205T3/pl unknown
- 2007-12-28 US US11/990,652 patent/US8436034B2/en active Active
- 2007-12-28 CA CA2673580A patent/CA2673580C/en not_active Expired - Fee Related
- 2007-12-28 MX MX2009007050A patent/MX2009007050A/es active IP Right Grant
- 2007-12-28 EP EP07866322A patent/EP2121653B1/en active Active
- 2007-12-28 NZ NZ599860A patent/NZ599860A/xx not_active IP Right Cessation
- 2007-12-28 KR KR1020157020182A patent/KR20150090282A/ko not_active Application Discontinuation
- 2007-12-28 NZ NZ577719A patent/NZ577719A/en not_active IP Right Cessation
- 2007-12-28 ES ES11195099.4T patent/ES2536626T3/es active Active
- 2007-12-28 KR KR1020157020180A patent/KR20150090281A/ko not_active Application Discontinuation
-
2008
- 2008-01-02 PE PE2008000057A patent/PE20081609A1/es not_active Application Discontinuation
- 2008-02-22 US US12/072,065 patent/US7799809B2/en not_active Expired - Fee Related
- 2008-02-22 US US12/070,941 patent/US7728012B2/en not_active Expired - Fee Related
-
2009
- 2009-06-18 IL IL199447A patent/IL199447A/en not_active IP Right Cessation
- 2009-06-26 CO CO09066778A patent/CO6190617A2/es active IP Right Grant
- 2009-06-29 GT GT200900186A patent/GT200900186A/es unknown
- 2009-06-29 EC EC2009009476A patent/ECSP099476A/es unknown
-
2010
- 2010-05-14 HK HK10104679.8A patent/HK1138833A1/xx not_active IP Right Cessation
- 2010-07-15 AR ARP100102569A patent/AR077477A2/es unknown
-
2013
- 2013-02-01 RU RU2013104459/04A patent/RU2013104459A/ru not_active Application Discontinuation
- 2013-03-25 US US13/849,826 patent/US9139557B2/en not_active Expired - Fee Related
-
2014
- 2014-03-11 IL IL231463A patent/IL231463A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP099476A (es) | Compuestos carboxamida y su uso como inhibidores de calpaína | |
| ECSP11011503A (es) | Compuestos carboxamida y su uso como inhibidores de calpaína. | |
| CL2017003496A1 (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton. | |
| CR11499A (es) | Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c | |
| CL2012000033A1 (es) | Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer. | |
| ECSP088258A (es) | Inhibidores de serina proteasas | |
| CL2015003442A1 (es) | Derivados heterociclicos | |
| UY31180A1 (es) | Derivados de (1r, 2r)-n-(1-cianociclopropil)-2-ciclohexanocarboxamidas sustituidas, procedimiento de preparación, composiciones faramacéuticas conteniéndolos y aplicaciones. | |
| UY30846A1 (es) | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos | |
| SV2009003299A (es) | Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa | |
| AR055076A1 (es) | Derivados de1,1-dioxido de 1,4-benzotiazepina,procedimiento para prepararlos,composiciones farmaceuticas que los contienen y usos en terapeutica. | |
| CR9881A (es) | Polimorfos de la sal benzoato de 2-[[6-[(3r)-3amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y metodos de uso para los mismos | |
| HN2007000267A (es) | Compuestos de 4-metil piridopirimidinoma | |
| DOP2010000134A (es) | Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos | |
| UY28747A1 (es) | Nuevo proceso para la sintesis y nueva forma cristalina de agomelatina y composiciones farmaceuticas que las contienen | |
| ECSP088440A (es) | Imidazopirazinas como inhibidores de proteinquinasa | |
| ECSP11010948A (es) | Inhibidores de las enzimas de proteína cinasa activadas por | |
| BR112012002134B8 (pt) | compostos inibidores de apaf-1 | |
| DOP2009000165A (es) | Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos | |
| ECSP088246A (es) | Nuevos derivados de benzotiazolona | |
| UY30835A1 (es) | 8-alquinilxantinas y derivados | |
| BRPI0606170A2 (pt) | purificação diastereomérica de rosuvastatina | |
| AR065278A1 (es) | Sales de derivado de benzotiazol | |
| AR063942A1 (es) | Compuestos de oximilo aciclico inhibidores de proteasa del virus de hepatitis c | |
| ECSP088700A (es) | Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1 |